---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-059392"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:21:34.879976+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ORIC reports Q3 2023 net loss; cash $256.2M; ORIC-114 CNS responses

## Summary
- Cash, cash equivalents and investments $256.2M as of Sept 30, 2023; expected to fund operations into late 2025.
- R&D expenses $22.4M in Q3 2023, up from $14.7M in Q3 2022 due to pipeline advancement.
- ORIC-114 Phase 1b data at ESMO showed CNS complete response in EGFR exon 20 NSCLC patient; favorable safety.
- Initial ORIC-533 data in multiple myeloma to be presented at ASH December 2023.
- ORIC-944 initial Phase 1b data in prostate cancer expected Q1 2024.

## SEC filing metadata
- accession: 0000950170-23-059392
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000095017023059392/0000950170-23-059392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000095017023059392/oric-20231106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-059392
- JSON: https://secwatch.observer/filing/0000950170-23-059392.json
- Plain text: https://secwatch.observer/filing/0000950170-23-059392.txt

## Key facts
- Earnings Releases
  Oric Pharmaceuticals, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000095017023059392/0000950170-23-059392-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.